Navigation Links
Trius Doses First Patient in Antibacterial Phase 2 Trial
Date:9/21/2008

TR-701 Tested for Efficacy in Drug Resistant Skin Infections

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment.

The study follows the recently completed two-part Phase 1 study that tested the safety, tolerability and pharmacokinetics of TR-701 in single and multiple ascending doses for up to 21 days compared with Zyvox(R) (linezolid), the only marketed drug of the oxazolidinone class. In addition, separate food effect and microdialysis studies measuring the absorption of TR-701 in the presence and absence of food and the tissue penetration of the drug, respectively, have also been completed.

Results of the Phase 1 trials will be presented at the joint annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C in October 2008.

"Our Phase 1 study results indicate that TR-701 will be a once-daily drug with the potential to offer patients several important advantages over linezolid as well as other marketed drugs," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "The intent of Phase 2 will be to validate these observations in a patient population and to select a therapeutic dosing regimen from the three doses being tested."

"The growing epidemic of MRSA in the hospital and community leaves few viable treatment options for patients requiring an oral drug," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We believe that the once-daily dosing and short course of TR-701 therapy of five to seven days will offer a clinical advantage for patients and a potential pharmaco-economic advantage for insurers and others concerned about the increasing cost of healthcare."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead drug candidate, TR-701, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs being developed to treat infections caused by Gram negative bacterial pathogens. For more information, visit http://www.triusrx.com/


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PacificGMP Completes GMP Product Fill for Trius Therapeutics
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
5. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
8. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
9. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):